Tel: 1-631-504-6093

p53 target new drug! Aprea’s Blood Cancer Combination Therapy Receives FDA Breakthrough Therapy Designation

Aprea Therapeutics is a Boston-based biopharmaceutical company focused on developing and commercializing innovative cancer therapies that reactivate the tumor suppressor protein p53. Recently, the company announced that the U.S. food […]

Read More →

Science Translational Medicine: Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition

In a new study, using advances in nanotechnology, researchers have found that restoring p53 not only delays the growth of p53-deficient liver and lung cancer cells, but may also make cancer drugs mTOR inhibitors […]

Read More →